| Immune thrombocytopenic purpura
Tavalisse vs Gamunex - C
Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.Deep comparison between: Tavalisse vs Gamunex-C with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGamunex-C has a higher rate of injection site reactions vs Tavalisse based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gamunex-C but not Tavalisse, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tavalisse
Gamunex-C
At A Glance
Oral
Twice daily
SYK inhibitor
IV infusion / SC injection
Every 3-4 weeks
Immune globulin
Indications
- Immune thrombocytopenic purpura
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Immune thrombocytopenic purpura Initiate at 100 mg orally twice daily; after 4 weeks, increase to 150 mg twice daily if platelet count has not reached at least 50 x 10 9 /L; use the lowest dose to maintain platelet count at least 50 x 10 9 /L; discontinue after 12 weeks if platelet count does not increase sufficiently to avoid clinically important bleeding.
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency, Congenital agammaglobulinemia IV: 300-600 mg/kg every 3-4 weeks; SC: initial weekly dose = prior monthly IGIV dose (g) x 1.37 divided by the number of weeks between IV doses, adjusted based on clinical response and IgG trough levels.
Immune thrombocytopenic purpura IV only: total dose of 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV loading dose: 2 g/kg over 2-4 consecutive days; maintenance: 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Contraindications
—
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
Adverse Reactions
Most common (>=5%) Diarrhea, hypertension, nausea, dizziness, ALT increased, AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, neutropenia
Serious Febrile neutropenia, diarrhea, pneumonia, hypertensive crisis
Most common (>=5%) Headache, pyrexia, nausea, cough, rhinitis, pharyngitis, asthma, diarrhea, sinusitis, vomiting, ecchymosis, rash, arthralgia, chills, hypertension, asthenia, fatigue, local infusion site reactions (SC administration), upper respiratory tract infection, back pain, dyspepsia, abdominal pain.
Serious Exacerbation of autoimmune pure red cell aplasia, pulmonary embolism, hemolytic anemia.
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, acute respiratory distress syndrome, TRALI, pulmonary edema, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, coma, seizures, aseptic meningitis, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, pancytopenia, leukopenia, hemolytic anemia, hepatic dysfunction.
Pharmacology
Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK); its major active metabolite R406 inhibits signal transduction of Fc-activating receptors and B-cell receptor, reducing antibody-mediated destruction of platelets.
GAMUNEX-C supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanisms of action in ITP and CIDP have not been fully elucidated.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tavalisse
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Gamunex-C
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (7/12) · Qty limit (0/12)
UnitedHealthcare
Tavalisse
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Gamunex-C
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Tavalisse
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Gamunex-C
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$15/fillfill
Tavalisse Copay AssistanceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Gamunex-C.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TavalisseView full Tavalisse profile
Gamunex-CView full Gamunex-C profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.